TORONTO, Sept. 18 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today
announced that it has initiated an additional trial of the investigational
drug capravirine, for the treatment of HIV infection, as part of combination
therapy in people who have failed previous therapy. Capravirine will be
investigated in a double-blind 48-week study, HIV-infected people for whom
combination therapy of one NNRTI plus two NRTIs (nucleoside reverse
transcriptase inhibitors) has failed to continue suppressing HIV levels in the
blood.
This trial will be in addition to several trials underway and actively
enrolling, designed to evaluate the safety and efficacy of capravirine, a
non-nucleoside reverse transcriptase inhibitor (NNRTI), in two distinct
populations: HIV-infected patients who have either never previously been
treated with anti-HIV medications (treatment-naive) or who have failed
previous treatment.
People living with HIV require individualized treatment plans that are
based on the unique circumstances of their previous care, including diverse
treatments and outcomes. In preclinical studies, capravirine demonstrated a
unique resistance profile, with potent antiviral activity against wild-type
HIV as well as HIV strains with mutations in reverse transcriptase, including
K103N, that confer broad viral resistance to other, commercially available
NNRTIs to which patients failing on current treatment may have been exposed.
In previous clinical studies of treatment-naive patients, capravirine showed
antiretroviral activity when used alone for a short period of time, and
achieved target antiretroviral concentrations in plasma as a part of
combination therapy.
Capravirine has been generally well-tolerated in clinical studies to date,
with the most commonly reported drug-related adverse events being nausea,
vomiting, and headache.
For more information on clinical trials using the investigational drug
capravirine, dial toll-free 1-888-847-2237.
Agouron Pharmaceuticals, Inc., a Pfizer company (NYSE: PFE), is committed
to the discovery, development, and marketing of innovative therapeutic
products engineered to inactivate proteins that play key roles in cancer,
AIDS, and other serious diseases. Agouron employs more than 1400 people of
whom approximately 850 are engaged in research and development.
Pfizer Inc, the world's largest pharmaceutical company, discovers,
develops, manufactures and markets leading prescription medicines, for humans
and animals, and many of the world's best known over-the-counter brands. This
year, Pfizer expects global sales of more than $30 billion and has a research
and development budget of $4.7 billion.
SOURCE Agouron Pharmaceuticals, Inc.
 back to top
Related links:
http://www.agouron.com
Company News On-Call:
http://www.prnewswire.com/comp/019650.html or fax,
800-758-5804, ext. 019650
CONTACT:
Joy Schmitt of Agouron Pharmaceuticals, Inc.,
858-622-3220
|
